国际流行病学传染病学杂志
國際流行病學傳染病學雜誌
국제류행병학전염병학잡지
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY AND INFECTIOUS DISEASE
2012年
2期
102-104
,共3页
肝硬化%双歧杆菌三联活菌胶囊%肠黏膜屏障
肝硬化%雙歧桿菌三聯活菌膠囊%腸黏膜屏障
간경화%쌍기간균삼련활균효낭%장점막병장
Liver cirrhosis%Bifidobacterium triple viable capsule%Intestinal mucosa barrier
目的 探讨双歧杆菌三联活菌胶囊对肝硬化患者肠黏膜屏障功能的保护作用.方法 选择80例住院治疗的肝硬化患者,分为观察组和对照组.对照组患者予以护肝、利尿等常规对症治疗,观察组在对照组治疗基础上口服三联活菌胶囊0.42g/次,3次/d,疗程均为8周.结果 治疗8周后,两组患者ALT、AST和Child-Pugh评分均较治疗前明显下降(观察组:t=2.39、2.43、2.12,P＜ 0.05;对照组:t=3.37、3.28、2.94,P＜0.01),且观察组改善的幅度明显优于对照组(t=2.30、2.25、2.29,P＜0.05)；同时两组患者血浆内毒素、降钙素原和尿L/M比值均较治疗前明显下降(观察组:t=2.11、2.34、2.45,P＜ 0.05；对照组:t=2.89、4.02、4.16,P＜0.01),且观察组改善幅度明显优于对照组(t=2.13、2.46、2.47,P＜0.05).结论 双歧杆菌三联活菌能保护肠上皮细胞,纠正肝硬化患者肠黏膜通透性异常,改善肠源性内毒素血症,保护肠黏膜屏障功能,加速肝功能恢复,对肝硬化有辅助的治疗作用.
目的 探討雙歧桿菌三聯活菌膠囊對肝硬化患者腸黏膜屏障功能的保護作用.方法 選擇80例住院治療的肝硬化患者,分為觀察組和對照組.對照組患者予以護肝、利尿等常規對癥治療,觀察組在對照組治療基礎上口服三聯活菌膠囊0.42g/次,3次/d,療程均為8週.結果 治療8週後,兩組患者ALT、AST和Child-Pugh評分均較治療前明顯下降(觀察組:t=2.39、2.43、2.12,P＜ 0.05;對照組:t=3.37、3.28、2.94,P＜0.01),且觀察組改善的幅度明顯優于對照組(t=2.30、2.25、2.29,P＜0.05)；同時兩組患者血漿內毒素、降鈣素原和尿L/M比值均較治療前明顯下降(觀察組:t=2.11、2.34、2.45,P＜ 0.05；對照組:t=2.89、4.02、4.16,P＜0.01),且觀察組改善幅度明顯優于對照組(t=2.13、2.46、2.47,P＜0.05).結論 雙歧桿菌三聯活菌能保護腸上皮細胞,糾正肝硬化患者腸黏膜通透性異常,改善腸源性內毒素血癥,保護腸黏膜屏障功能,加速肝功能恢複,對肝硬化有輔助的治療作用.
목적 탐토쌍기간균삼련활균효낭대간경화환자장점막병장공능적보호작용.방법 선택80례주원치료적간경화환자,분위관찰조화대조조.대조조환자여이호간、이뇨등상규대증치료,관찰조재대조조치료기출상구복삼련활균효낭0.42g/차,3차/d,료정균위8주.결과 치료8주후,량조환자ALT、AST화Child-Pugh평분균교치료전명현하강(관찰조:t=2.39、2.43、2.12,P＜ 0.05;대조조:t=3.37、3.28、2.94,P＜0.01),차관찰조개선적폭도명현우우대조조(t=2.30、2.25、2.29,P＜0.05)；동시량조환자혈장내독소、강개소원화뇨L/M비치균교치료전명현하강(관찰조:t=2.11、2.34、2.45,P＜ 0.05；대조조:t=2.89、4.02、4.16,P＜0.01),차관찰조개선폭도명현우우대조조(t=2.13、2.46、2.47,P＜0.05).결론 쌍기간균삼련활균능보호장상피세포,규정간경화환자장점막통투성이상,개선장원성내독소혈증,보호장점막병장공능,가속간공능회복,대간경화유보조적치료작용.
Objective To evaluate the protective effect of bifidobacterium triple viable capsule on intestinal mucosa barrior of cirrhosis patient.Methods Eighty liver cirrhosis patients were divided into control group and treatment group randomly.All the patients received conventional therapy for liver cirrhosis as liver protecting,diuresis and so on.The treatment group took extra bifidohacterium triple viable capsule orally 0.42g each,3 times a day for 8 weeks.Results After 8 weeks treatment,the ALT,AST and Child-Pugh scores of both of the two groups reduced significantly compared with pretreatment (treatment group:t =2.39,2.43,2.12,P ＜ 0.05; control group:t=3.37,3.28,2.94,P ＜0.01 ) ; and the reducing level was more obviously in treatment group than in control group( t =2.30,2.25,2.29,P ＜0.05); meanwhile,the plasma endotoxin,PCT and urine L/M of the two groups reducd significantly(treatment group:t=2.11,2.34,2.45,P ＜ 0.05;control group:t=2.89,4.02,4.16,P ＜ 0.01); and the reducing level was more obviously in treatment group than in control group(t=2.13,2.46,2.47,P＜0.05).Conclusions Bifidobacterium triple viable vaccine intake can protect the colonic epithelial cell,reverse the intestinal membrane permeability,amelio-rate the endotoxemia,protect the intestinal mucosa barrier,and promote the recovery of liver function,it can be an adjuvant therapy of liver cirrhosis.
